A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.
🦱 탈모
🔵 RCT
무작위 임상시험
4/5 보강
TL;DR
5% MTF is a safe and effective treatment for men with androgenetic alopecia and was well tolerated over a 52-week period.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
143 subjects continued on an open-label phase to collect 52 weeks of safety information on 5% MTF.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[LIMITATIONS] There was no collection of efficacy data beyond 16 weeks. [CONCLUSIONS] We believe that 5% MTF is a safe and effective treatment for men with AGA.
📑 코퍼스 인용 관계
· 인용됨 44
📑 인용한 논문 (6) ▾
- Comparison of the efficacy of platelet-rich plasma with topical minoxidil in treating pati… Skin health and disease · 2025
- Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral … Frontiers in pharmacology · 2025
- Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%… Dermatology practical & conceptual · 2025
- Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alo… Cureus · 2025
- Topical minoxidil effectiveness in enhancing facial aesthetics: A systematic review and me… Journal of family medicine and primary care · 2025
- Novel Electrotrichogenic Device Promotes Hair Growth in Men With Androgenetic Alopecia: A … Journal of cosmetic dermatology · 2025
연도별 인용 (2012–2026) · 합계 194
OpenAlex 토픽 ·
Hair Growth and Disorders
Facial Rejuvenation and Surgery Techniques
Dermatologic Treatments and Research
Abstract 🌐 Abstract
[BACKGROUND] An alternative to currently marketed topical minoxidil solutions is desirable.
[OBJECTIVE] To assess the efficacy and safety of a new 5% minoxidil topical formulation in a propylene glycol-free foam vehicle in men with androgenetic alopecia (AGA).
[METHODS] This was a 16-week, double-blind, placebo-controlled trial of 5% minoxidil topical foam (MTF) in 352 men, 18 to 49 years old. At week 16, 143 subjects continued on an open-label phase to collect 52 weeks of safety information on 5% MTF.
[RESULTS] At week 16 compared with baseline, there was a statistically significant increase in (1) hair counts in the 5% MTF group versus placebo (P < .0001) and (2) subjective assessment of improved hair loss condition (P < .0001) in the 5% MTF group versus placebo. The 5% MTF was well tolerated over a 52-week period.
[LIMITATIONS] There was no collection of efficacy data beyond 16 weeks.
[CONCLUSIONS] We believe that 5% MTF is a safe and effective treatment for men with AGA.
[OBJECTIVE] To assess the efficacy and safety of a new 5% minoxidil topical formulation in a propylene glycol-free foam vehicle in men with androgenetic alopecia (AGA).
[METHODS] This was a 16-week, double-blind, placebo-controlled trial of 5% minoxidil topical foam (MTF) in 352 men, 18 to 49 years old. At week 16, 143 subjects continued on an open-label phase to collect 52 weeks of safety information on 5% MTF.
[RESULTS] At week 16 compared with baseline, there was a statistically significant increase in (1) hair counts in the 5% MTF group versus placebo (P < .0001) and (2) subjective assessment of improved hair loss condition (P < .0001) in the 5% MTF group versus placebo. The 5% MTF was well tolerated over a 52-week period.
[LIMITATIONS] There was no collection of efficacy data beyond 16 weeks.
[CONCLUSIONS] We believe that 5% MTF is a safe and effective treatment for men with AGA.
- p-value P < .0001
5% MTF is a safe and effective treatment for men with androgenetic alopecia and was well tolerated over a 52-week period.
APA 7
Olsen, E. A., Whiting, D., Bergfeld, W., Miller, J., Hordinsky, M., Wanser, R., Zhang, P., & Kohut, B. (2007). A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.. Journal of the American Academy of Dermatology, 57(5), 767-74. https://doi.org/10.1016/j.jaad.2007.04.012
Vancouver
Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. Jour. Amer. Acad. Derm.. 2007;57(5):767-74. doi:10.1016/j.jaad.2007.04.012
AMA 11
Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. Jour. Amer. Acad. Derm.. 2007;57(5):767-74. doi:10.1016/j.jaad.2007.04.012
Chicago
Olsen, E. A., Whiting, D., Bergfeld, W., Miller, J., Hordinsky, M., Wanser, R., Zhang, P., and Kohut, B.. 2007. "A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men." Journal of the American Academy of Dermatology 57 (5): 767-74. https://doi.org/10.1016/j.jaad.2007.04.012
MLA 9
Olsen, E. A., et al. "A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men." Journal of the American Academy of Dermatology, vol. 57, no. 5, 2007, pp. 767-74. doi:10.1016/j.jaad.2007.04.012.
PMID
17761356 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 7/8 (88%)
· 참조 0편 · 후속 7편
이 논문을 인용한 후속 연구 20
- Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considera…
- Minoxidil and its use in hair disorders: a review.
- Androgenetic Alopecia: An Update of Treatment Options.
- Alopecia Areata: An Updated Review for 2023.
- A Clinical and Biological Guide for Understanding Chemotherapy-Induced Alopecia and Its Prevention.
- Topical Treatment for Scarring and Non-Scarring Alopecia: An Overview of the Current Evidence.
- Role and Mechanisms of Phytochemicals in Hair Growth and Health.
- The Biology and Genomics of Human Hair Follicles: A Focus on Androgenetic Alopecia.
- Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alo…
- Advances in hair growth.
- Can Plant Extracts Help Prevent Hair Loss or Promote Hair Growth? A Review Comparing Their Therapeut…
- Effectiveness of a Layer-by-Layer Microbubbles-Based Delivery System for Applying Minoxidil to Enhan…
- Minoxidil Downregulates Interleukin-1 Alpha Gene Expression in HaCaT Cells.
- Use of Botulinum Toxin for Androgenic Alopecia: A Systematic Review.
- Meta-Analysis on the Efficacy and Safety of Traditional Chinese Medicine as Adjuvant Therapy for Ref…
- Application of multi-omics techniques to androgenetic alopecia: Current status and perspectives.
- The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis.
- Short-Term Efficacy of Autologous Cellular Micrografts in Male and Female Androgenetic Alopecia: A R…
- Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil…
- Similar response patterns to topical minoxidil foam 5% in frontal and vertex scalp of men with andro…
같은 제1저자의 인용 많은 논문 (5)
- A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.
- The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
- SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss.
- Evaluation and treatment of male and female pattern hair loss.
- Objective outcome measures: Collecting meaningful data on alopecia areata.